The Effect of Pancreas Transplantation on 10-year Cardiovascular Disease Risk in Type 1 Diabetics Undergoing Simultaneous Pancreas Kidney Transplantation
CUA Online Library. Jiang A. 06/25/13; 31311; MP-06.10
CLICK HERE TO LOGIN
REGULAR CONTENT
REGULAR CONTENT
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Introduction and Objectives: It is uncertain whether pancreas transplants in type 1 diabetics requiring kidney transplantations improve overall patient health and survival. The aim of this study was to look at the impact of pancreas transplants on type 1 diabetics using the Framingham Risk Score (FRS) for 10-year cardiovascular disease (CVD) risk.
Methods: Between 2004 and 2012, 51 type 1 diabetics received simultaneous pancreas kidney (SPK) and 18 received solitary kidney (SK) transplants. The two groups were matched in terms of age and donor renal function. The FRS for 10-year CVD risk was calculated and compared between the two groups pre-operatively and one-year post-operatively. Individual risk factors were also compared to examine its effect on cardiac risk reduction.
Results: SPK and SK transplant patients received renal grafts that were equivalent in function as indicated by the donor glomerular filtration rate (GFR) (124.8±65.6 vs 111.4±40.9 mL/min/1.73 m2, p>0.05). Using the FRS calculator, we determined that pre-operative risk score for SPK transplant group was 12.5±8.6% compared with 8.9±7.0% one-year post-operatively (p = 0.0007). There was no significant difference in SK transplant group when comparing the pre and post-operative CVD risks. One year post-operatively, SPK recipients had reduced their total number of antihypertensive medications (p = 0.0000008) and statins (p = 0.001). SPK transplantations also decreased the recipients' triglyceride levels from 1.36±0.81 mmol/L to 0.99±0.37 mmol/L (p = 0.003). In contrast, SK recipients had no changes in the number of antihypertensive medications or statins, and no difference in triglyceride levels.
Conclusions: Pancreas transplantation has a positive impact on patient health based on the analysis of FRS for 10-year CVD risk. According to FRS, SPK transplantation reduced the CVD risk from intermediate (10-20%) to low (<10%) risk range. Its impact on cardiovascular complications continues to be studied.
Methods: Between 2004 and 2012, 51 type 1 diabetics received simultaneous pancreas kidney (SPK) and 18 received solitary kidney (SK) transplants. The two groups were matched in terms of age and donor renal function. The FRS for 10-year CVD risk was calculated and compared between the two groups pre-operatively and one-year post-operatively. Individual risk factors were also compared to examine its effect on cardiac risk reduction.
Results: SPK and SK transplant patients received renal grafts that were equivalent in function as indicated by the donor glomerular filtration rate (GFR) (124.8±65.6 vs 111.4±40.9 mL/min/1.73 m2, p>0.05). Using the FRS calculator, we determined that pre-operative risk score for SPK transplant group was 12.5±8.6% compared with 8.9±7.0% one-year post-operatively (p = 0.0007). There was no significant difference in SK transplant group when comparing the pre and post-operative CVD risks. One year post-operatively, SPK recipients had reduced their total number of antihypertensive medications (p = 0.0000008) and statins (p = 0.001). SPK transplantations also decreased the recipients' triglyceride levels from 1.36±0.81 mmol/L to 0.99±0.37 mmol/L (p = 0.003). In contrast, SK recipients had no changes in the number of antihypertensive medications or statins, and no difference in triglyceride levels.
Conclusions: Pancreas transplantation has a positive impact on patient health based on the analysis of FRS for 10-year CVD risk. According to FRS, SPK transplantation reduced the CVD risk from intermediate (10-20%) to low (<10%) risk range. Its impact on cardiovascular complications continues to be studied.
Introduction and Objectives: It is uncertain whether pancreas transplants in type 1 diabetics requiring kidney transplantations improve overall patient health and survival. The aim of this study was to look at the impact of pancreas transplants on type 1 diabetics using the Framingham Risk Score (FRS) for 10-year cardiovascular disease (CVD) risk.
Methods: Between 2004 and 2012, 51 type 1 diabetics received simultaneous pancreas kidney (SPK) and 18 received solitary kidney (SK) transplants. The two groups were matched in terms of age and donor renal function. The FRS for 10-year CVD risk was calculated and compared between the two groups pre-operatively and one-year post-operatively. Individual risk factors were also compared to examine its effect on cardiac risk reduction.
Results: SPK and SK transplant patients received renal grafts that were equivalent in function as indicated by the donor glomerular filtration rate (GFR) (124.8±65.6 vs 111.4±40.9 mL/min/1.73 m2, p>0.05). Using the FRS calculator, we determined that pre-operative risk score for SPK transplant group was 12.5±8.6% compared with 8.9±7.0% one-year post-operatively (p = 0.0007). There was no significant difference in SK transplant group when comparing the pre and post-operative CVD risks. One year post-operatively, SPK recipients had reduced their total number of antihypertensive medications (p = 0.0000008) and statins (p = 0.001). SPK transplantations also decreased the recipients' triglyceride levels from 1.36±0.81 mmol/L to 0.99±0.37 mmol/L (p = 0.003). In contrast, SK recipients had no changes in the number of antihypertensive medications or statins, and no difference in triglyceride levels.
Conclusions: Pancreas transplantation has a positive impact on patient health based on the analysis of FRS for 10-year CVD risk. According to FRS, SPK transplantation reduced the CVD risk from intermediate (10-20%) to low (<10%) risk range. Its impact on cardiovascular complications continues to be studied.
Methods: Between 2004 and 2012, 51 type 1 diabetics received simultaneous pancreas kidney (SPK) and 18 received solitary kidney (SK) transplants. The two groups were matched in terms of age and donor renal function. The FRS for 10-year CVD risk was calculated and compared between the two groups pre-operatively and one-year post-operatively. Individual risk factors were also compared to examine its effect on cardiac risk reduction.
Results: SPK and SK transplant patients received renal grafts that were equivalent in function as indicated by the donor glomerular filtration rate (GFR) (124.8±65.6 vs 111.4±40.9 mL/min/1.73 m2, p>0.05). Using the FRS calculator, we determined that pre-operative risk score for SPK transplant group was 12.5±8.6% compared with 8.9±7.0% one-year post-operatively (p = 0.0007). There was no significant difference in SK transplant group when comparing the pre and post-operative CVD risks. One year post-operatively, SPK recipients had reduced their total number of antihypertensive medications (p = 0.0000008) and statins (p = 0.001). SPK transplantations also decreased the recipients' triglyceride levels from 1.36±0.81 mmol/L to 0.99±0.37 mmol/L (p = 0.003). In contrast, SK recipients had no changes in the number of antihypertensive medications or statins, and no difference in triglyceride levels.
Conclusions: Pancreas transplantation has a positive impact on patient health based on the analysis of FRS for 10-year CVD risk. According to FRS, SPK transplantation reduced the CVD risk from intermediate (10-20%) to low (<10%) risk range. Its impact on cardiovascular complications continues to be studied.
Code of conduct/disclaimer available in General Terms & Conditions
{{ help_message }}
{{filter}}